The Impact of the Nitric Oxide (NO)/Soluble Guanylyl Cyclase (sGC) Signaling Cascade on Kidney Health and Disease: A Preclinical Perspective

• Main Authors: Shalini M. Krishnan, Jan R. Kraehling, Frank Eitner, Agnès Bénardeau, Peter Sandner
• Format: Article
• Language: English
• Published: MDPI AG 2018-06-01
• Series: International Journal of Molecular Sciences
• Subjects: nitric oxide; cGMP; chronic kidney disease; soluble guanylyl cyclase; sGC; sGC stimulator; sGC activator
• Online Access: http://www.mdpi.com/1422-0067/19/6/1712

Chronic Kidney Disease (CKD) is a highly prevalent disease with a substantial medical need for new and more efficacious treatments. The Nitric Oxide (NO), soluble guanylyl cyclase (sGC), cyclic guanosine monophosphate (cGMP) signaling cascade regulates various kidney functions. cGMP directly influences renal blood flow, renin secretion, glomerular function, and tubular exchange processes. Downregulation of NO/sGC/cGMP signaling results in severe kidney pathologies such as CKD. Therefore, treatment strategies aiming to maintain or increase cGMP might have beneficial effects for the treatment of progressive kidney diseases. Within this article, we review the NO/sGC/cGMP signaling cascade and its major pharmacological intervention sites. We specifically focus on the currently known effects of cGMP on kidney function parameters. Finally, we summarize the preclinical evidence for kidney protective effects of NO-donors, PDE inhibitors, sGC stimulators, and sGC activators.